Catalyzing the critical path initiative: FDA's progress in drug development activities

E-ISSN： 1532-6535|97|3|221-233

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.97, Iss.3, 2015-03, pp. : 221-233

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Critical Path Initiative: Leveraging Collaborations to Enhance Regulatory Science

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 91, Iss. 3, 2012-03 ,pp. : 380-383

John Wiley & Sons Inc

Access to resources Recommend Favorite

FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 1, 2015-01 ,pp. : 29-36

John Wiley & Sons Inc

Access to resources Recommend Favorite

Meeting report: FDA public meeting on patient‐focused drug development and medication adherence in solid organ transplant patients

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 18, Iss. 3, 2018-03 ,pp. : 564-573

John Wiley & Sons Inc

Access to resources Recommend Favorite

New FDA Initiative and Website to Help Prevent Surgical Fires

JCAH Perspectives, Vol. 32, Iss. 2, 2012-02 ,pp. : 7-7

Joint Commission Resources

Access to resources Recommend Favorite

Measuring symptoms as a critical component of drug development and evaluation in hematological diseases

By Williams Loretta A Yucel Emre Cortes Jorge E Cleeland Charles S

Clinical Investigation, Vol. 3, Iss. 12, 2013-12 ,pp. : 1127-1138

Future Science

Access to resources Recommend Favorite